SNGX News and Press, Soligenix Inc. From 05/11/23

2023-05-11 09:24:33 ET Soligenix ( NASDAQ: SNGX ) said the U.S. Food and Drug Administration (FDA) has granted a Type A meeting to discuss the design of a second phase 3 trial of photodynamic therapy HyBryte ointment to treat cutaneous T-cell lymphoma (CTCL) The company e...

Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma PR Newswire Update on FDA Meeting Outcome Expected Next Month PR...

Soligenix Announces Closing of $8.5 Million Public Offering PR Newswire PRINCETON, N.J. , May 9, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produ...

2023-05-04 13:03:52 ET Gainers: Actelis Networks ( ASNS ) +85% . Soligenix ( SNGX ) +65% . SaverOne 2014 Ltd ( SVRE ) +43% . Guardforce AI ( GFAI ) +41% . Arconic Corporation ( ARNC ) +28% . Shopify ( SHOP ) +25% . ...

2023-05-04 10:00:25 ET Gainers: Soligenix ( SNGX ) +117% . ZimVie ( ZIMV ) +27% . Lantheus ( LNTH ) +14% . MiNK Therapeutics ( INKT ) +16% . Reviva Pharmaceuticals ( RVPH ) +10% . Losers: Sensus Healthcare ( SRTS ...

2023-05-04 08:49:45 ET Soligenix ( NASDAQ: SNGX ) reported data from a compatibility study of its photodynamic therapy HyBryte ointment to treat cutaneous T-cell lymphoma (CTCL) using the Daavlin Series 7 visible light device. HyBryte (SGX301) is a photodynamic therapy whic...

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma PR Newswire Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J. , May 4, 2023 /PRN...

Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors PR Newswire Strengthens regulatory and orphan drug development expertise PRINCETON, N.J. , May 3, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligen...

Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease PR Newswire Phase 2/3-Ready Orphan Disease Program Complements Company's Existing Late-Stage Rare Disease Pipelin...

2023-04-24 09:25:20 ET Soligeni ( NASDAQ: SNGX ) is trading 12% higher premarket after it said it had submitted a meeting request to the U.S. Food and Drug Administration to begin discussions regarding the design of a second, Phase 3 trial testing HyBryte to treat a rare cance...